{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:08:17Z","timestamp":1776308897712,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00417-022-05682-x","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T08:04:31Z","timestamp":1651219471000},"page":"3285-3291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of treatment effects between 4.9% N-acetyl-aspartyl glutamic acid and 0.05% cyclosporine A eye drops in dry eye patients"],"prefix":"10.1007","volume":"260","author":[{"given":"Daeun","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5864-6758","authenticated-orcid":false,"given":"Ji","family":"Sang Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"5682_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","volume":"5","author":"MA Lemp","year":"2007","unstructured":"Lemp MA, Foulks GN (2007) The definition and classification of dry eye disease. Ocul Surf 5:75\u201392","journal-title":"Ocul Surf"},{"key":"5682_CR2","doi-asserted-by":"publisher","first-page":"DES192","DOI":"10.1167\/iovs.17-23651","volume":"59","author":"T Yamaguchi","year":"2018","unstructured":"Yamaguchi T (2018) Inflammatory response in dry eye. Invest Ophthalmol Vis Sci 59:DES192\u2013DES199","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5682_CR3","doi-asserted-by":"crossref","unstructured":"Chen D, Zhang S, Bian A, Hong J, Deng Y, Zhang M, Chen W, Shao Y, Zhao J (2019) Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: a 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study. Medicine 98:e16710","DOI":"10.1097\/MD.0000000000016710"},{"key":"5682_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jtos.2014.12.006","volume":"13","author":"KH Wan","year":"2015","unstructured":"Wan KH, Chen LJ, Young AL (2015) Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf 13:213\u2013225","journal-title":"Ocul Surf"},{"key":"5682_CR5","first-page":"573","volume":"8","author":"M Bonnet","year":"1985","unstructured":"Bonnet M, Ducournau D, Lumbroso P, Serpin G (1985) N-acetyl-aspartylglutamic acid eye drops in allergic-type conjuctivitis. Double-blind comparative clinical study. J Fr Ophtalmol 8:573\u2013578","journal-title":"J Fr Ophtalmol"},{"key":"5682_CR6","first-page":"475","volume":"87","author":"P Berard","year":"1987","unstructured":"Berard P, Berard P Jr, Mouillac-Gambarelli N, Jourdan-Fonta D (1987) Seasonal and chronic allergic conjunctivitis in adults with children. Multicenter evaluation of the collyrium N-acetylaspartylglutamic acid (NAAGA) in ophthalmologic and allergy practices. Bull Soc Ophtalmol Fr 87:475\u2013483","journal-title":"Bull Soc Ophtalmol Fr"},{"key":"5682_CR7","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/bjo.2007.117515","volume":"91","author":"A Leonardi","year":"2007","unstructured":"Leonardi A, Bremond-Gignac D, Bortolotti M, Violato D, Pouliquen P, Delval L, Grouin J-M, Fregona I (2007) Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients. Br J Ophthalmol 91:1662\u20131666","journal-title":"Br J Ophthalmol"},{"key":"5682_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000267878","volume":"28","author":"K G\u00fcnd\u00fcz","year":"1996","unstructured":"G\u00fcnd\u00fcz K, U\u00e7akhan \u00d6, Budak K, Eryilmaz T, \u00d6zkan M (1996) Efficacy of lodoxamide 0.1% versus N-acetyl aspartyl glutamic acid 6% ophthalmic solutions in patients with vernal keratoconjunctivitis. Ophthalmic Res 28:80\u201387","journal-title":"Ophthalmic Res"},{"key":"5682_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF01968092","volume":"24","author":"M Etievant","year":"1988","unstructured":"Etievant M, Leluc B, David B (1988) In vitro inhibition of the classical and alternate pathways of activation of human complement by N acetyl aspartyl glutamic acid (NAAGA). Agents Actions 24:137\u2013144","journal-title":"Agents Actions"},{"key":"5682_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jfo.2009.09.006","volume":"32","author":"F Brignole-Baudouin","year":"2009","unstructured":"Brignole-Baudouin F, Robert P, Creuzot-Garcher C, Olmiere C, Delval L, Baudouin C (2009) Evaluation of NAAGA efficacy in dry eye syndrome. J Fr Ophtalmol 32:613\u2013620","journal-title":"J Fr Ophtalmol"},{"key":"5682_CR11","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.2147\/OPTH.S308088","volume":"15","author":"C Matossian","year":"2021","unstructured":"Matossian C, Trattler W, Loh J (2021) Dry eye treatment with topical cyclosporine 0.1% in chondroitin sulfate ophthalmic emulsion. Clin Ophthalmol 15:1979","journal-title":"Clin Ophthalmol"},{"key":"5682_CR12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","volume":"22","author":"AJ Bron","year":"2003","unstructured":"Bron AJ, Evans VE, Smith JA (2003) Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22:640\u2013650","journal-title":"Cornea"},{"key":"5682_CR13","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1167\/iovs.10-6997b","volume":"52","author":"JD Nelson","year":"2011","unstructured":"Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, Foulks GN (2011) The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci 52:1930\u20131937","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5682_CR14","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.ophtha.2017.08.029","volume":"124","author":"MK Rhee","year":"2017","unstructured":"Rhee MK, Mah FS (2017) Inflammation in dry eye disease: how do we break the cycle? Ophthalmology 124:S14\u2013S19","journal-title":"Ophthalmology"},{"key":"5682_CR15","first-page":"1458","volume":"38","author":"C Baudouin","year":"1997","unstructured":"Baudouin C, Brignole F, Becquet F, Pisella P-J, Goguel A (1997) Flow cytometry in impression cytology specimens. A new method for evaluation of conjunctival inflammation. Invest Ophthalmol Vis Sci 38:1458\u20131464","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5682_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000027387","volume":"213","author":"K Tsubota","year":"1999","unstructured":"Tsubota K, Fujihara T, Saito K, Takeuchi T (1999) Conjunctival epithelium expression of HLA-DR in dry eye patients. Ophthalmologica 213:16\u201319","journal-title":"Ophthalmologica"},{"key":"5682_CR17","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1167\/iovs.15-16555","volume":"58","author":"F Brignole-Baudouin","year":"2017","unstructured":"Brignole-Baudouin F, Riancho L, Ismail D, Deniaud M, Amrane M, Baudouin C (2017) Correlation between the inflammatory marker HLA-DR and signs and symptoms in moderate to severe dry eye disease. Invest Ophthalmol Vis Sci 58:2438\u20132448","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5682_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5301\/ejo.5000779","volume":"26","author":"A Leonardi","year":"2016","unstructured":"Leonardi A, Van Setten G, Amrane M, Ismail D, Garrigue J-S, Figueiredo FC, Baudouin C (2016) Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 26:287\u2013296","journal-title":"Eur J Ophthalmol"},{"key":"5682_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/jop.2019.0060","volume":"36","author":"LM Periman","year":"2020","unstructured":"Periman LM, Perez VL, Saban DR, Lin MC, Neri P (2020) The immunological basis of dry eye disease and current topical treatment options. J Ocul Pharmacol Ther 36:137\u2013146","journal-title":"J Ocul Pharmacol Ther"},{"key":"5682_CR20","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1167\/iovs.13-11681","volume":"54","author":"J Gao","year":"2013","unstructured":"Gao J, Sana R, Calder V, Calonge M, Lee W, Wheeler LA, Stern ME (2013) Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin A. Invest Ophthalmol Vis Sci 54:4717\u20134733","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5682_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5114\/ceji.2016.60995","volume":"41","author":"AM Ambroziak","year":"2016","unstructured":"Ambroziak AM, Szaflik J, Szaflik JP, Ambroziak M, Witkiewicz J, SkoPi\u0144Ski P (2016) Immunomodulation on the ocular surface: a review. Cent Eur J Immunol 41:195","journal-title":"Cent Eur J Immunol"},{"key":"5682_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S0014-5793(97)00930-7","volume":"413","author":"S Meyer","year":"1997","unstructured":"Meyer S, Kohler NG, Joly A (1997) Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-\u03baB activation. FEBS Lett 413:354\u2013358","journal-title":"FEBS Lett"},{"key":"5682_CR23","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/ICO.0b013e3181a16472","volume":"28","author":"MH Dastjerdi","year":"2009","unstructured":"Dastjerdi MH, Hamrah P, Dana R (2009) High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 28:1091","journal-title":"Cornea"},{"key":"5682_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y (2017) TFOS DEWS II management and therapy report. Ocul Surf 15:575\u2013628","journal-title":"Ocul Surf"},{"key":"5682_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-015-0122-z","volume":"15","author":"A Sy","year":"2015","unstructured":"Sy A, O\u2019Brien KS, Liu MP, Cuddapah PA, Acharya NR, Lietman TM, Rose-Nussbaumer J (2015) Expert opinion in the management of aqueous deficient dry eye disease (DED). BMC Ophthalmol 15:1\u20136","journal-title":"BMC Ophthalmol"},{"key":"5682_CR26","unstructured":"Wan P, Wang X, Song Y, Li Z, Duan H, Zhang W, Liu Z, Wang Z (2012) Study on the treatment of dry eye with loteprednol etabonate. Zhonghua Yan Ke Za Zhi 48:142\u2013147"},{"key":"5682_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1089\/jop.2010.0085","volume":"27","author":"JD Sheppard","year":"2011","unstructured":"Sheppard JD, Scoper SV, Samudre S (2011) Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. J Ocul Pharmacol Ther 27:23\u201327","journal-title":"J Ocul Pharmacol Ther"},{"key":"5682_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/bjo.2007.132621","volume":"92","author":"CE Pavesio","year":"2008","unstructured":"Pavesio CE, DeCory HH (2008) Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 92:455\u2013459","journal-title":"Br J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05682-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05682-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05682-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T05:03:39Z","timestamp":1663218219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05682-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["5682"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05682-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"12 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Kim\u2019s Eye Hospital institutional review board (No. 2021\u201311-017\u2013003) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study was a retrospective study and informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}